ST. LOUIS (September 22, 2014) – Mallinckrodt (NYSE: MNK) today announced the U.S. launch of the OptiSyncTM data management system as a new technology in its Global Medical Imaging segment. The OptiSync system is designed to help healthcare professionals efficiently collect and analyze radiology data from when a patient undergoes a contrast media-enhanced computed tomography (CT) diagnostic imaging procedure.

The OptiSync system is used with the OptiVantage™ dual-head CT contrast delivery system, and allows users to verify and log patient and pharmaceutical information with the scan of a barcode. As injection data is collected, the OptiSync system transmits patient, drug, dose and administration information to HL7-based healthcare systems and automates patient record updates. By assembling a database that includes contrast media usage, spend, workflow and benchmarking across all users, scanners and facilities, the OptiSync system can help users identify areas where they can reduce errors, increase productivity or improve efficiency.

“The OptiSync data management system was created with patients and customers in mind,” said Dan Brague, Mallinckrodt Vice President and General Manager, Imaging – North America. “We are pleased to launch this important tool to help empower decision-making in radiology departments with easier data collection and more efficient contrast media management and usage.”

Learn more about the OptiSync data management system at OptiSync.com.

ABOUT MALLINCKRODT
Mallinckrodt is a global specialty pharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology along with analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Pharmaceuticals segment includes branded and specialty generic drugs and active pharmaceutical ingredients, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt has more than 5,500 employees worldwide and a commercial presence in roughly 65 countries. The company's fiscal 2013 revenue totaled $2.2 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.